Resources from the same session
1605 - MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer
Presenter: George Sledge
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
7184 - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)
Presenter: Dennis Slamon
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
1812 - KEYNOTE-522: Phase 3 study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
2520 - Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer
Presenter: Veronique Dieras
Session: Presidential Symposium II
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8_PR and LBA9
Presenter: Sherene Loi
Session: Presidential Symposium II
Resources:
Slides
Webcast